mifamurtide (Mepact)

Introduction

Approved in Europe. Not FDA-approved in US.

Granted orphan drug status by the FDA in 2001

Denied approval by the FDA in 2007

Indications

• osteosarcoma, post surgical resection

Dosage

• liposomal infusion

Adverse effects

• fever (~90%)
• vomiting, fatigue and tachycardia (~50%)
• infections, anemia, anorexia, headache, diarrhea, constipation (>10%)

Mechanism of action

• synthetic dipeptide derivative that binds NOD2

More general terms

• antineoplastic agent (chemotherapeutic agent)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23725093
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23663962
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11672602
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6917905
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5479141